About amcure

Amcure is a privately held, clinical-stage company developing peptide-based compounds for the treatment of highly metastatic forms of squamous cancer.

Lead candidate AMC303 is being developed as a treatment for patients with advanced and metastatic squamous tumors, e.g. head and neck cancer, esophageal cancer, cervical cancer, and lung cancer. AMC303 has a high specificity for inhibiting CD44v6, a co-receptor required for signaling through multiple cellular pathways (c-Met, VEGFR-2, RON). CD44v6 maintains an immunosuppressive and tumor-permissive microenvironment promoting angiogenesis and the development of metastases. By blocking CD44v6, AMC303 inhibits tumor growth via direct and indirect effects on the stroma. AMC303 is currently in a Phase Ib trial and has demonstrated strong effects in in vivo proof-of-concept studies.

Established in 2012, amcure GmbH is a spin-off from the Karlsruhe Institute of Technology and is supported by a grant from the German Federal Ministry of Education and Research.